CUSIP: 36870A108
Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
4,648,608
-
Share change
-
-370,984
-
Total reported value
-
$47,136,000
-
Price per share
-
$10.19
-
Number of holders
-
37
-
Value change
-
-$1,167,810
-
Number of buys
-
23
-
Number of sells
-
12
Quarterly Holders Quick Answers
What is CUSIP 36870A108?
CUSIP 36870A108 identifies GEMP - GEMPHIRE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2018
-
Previous quarter:
Q1 2018
Recent filing periods for CUSIP 36870A108:
Institutional Holders of GEMPHIRE THERAPEUTICS INC - COM (GEMP) as of Q2 2018
As of 30 Jun 2018,
GEMPHIRE THERAPEUTICS INC - COM (GEMP) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,648,608 shares.
The largest 10 holders included
Cormorant Asset Management, LP, NORTHPOINTE CAPITAL LLC, Exchange Capital Management, Inc., BAMCO INC /NY/, VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, Cambridge Investment Research Advisors, Inc., Wilks Brothers, LLC, Marshall Wace North America L.P., and Stonepine Capital Management, LLC.
This page lists
37
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.